Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

  • CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health
  • Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”)
  • The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population
  • Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors.

Under the leadership of CEO Rob Etherington, the company focuses on improving mitochondrial health, which is crucial for neurological functions. Mitochondria play a vital role in cellular metabolism and energy production. In neurodegenerative diseases, impaired mitochondrial function is a significant…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.